Navigation Links
CSL Limited Signs Commercial License Agreement with Selexis SA
Date:7/26/2011

GENEVA, July 26, 2011 /PRNewswire/ -- Selexis SA, a global life science company with technologies for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins announced today that CSL Limited (ASX:CSL Australia) has entered a commercial license agreement with Selexis for the preclinical development of a therapeutic antibody anticipated to enter Phase I clinical trials in 2012. This commercial license agreement provides CSL with the rights to use a cell line, generated using the Selexis SUREtechnology Platform, for the cGMP production of an undisclosed antibody.

"We are pleased CSL is moving forward with a production cell line generated using the SUREtechnology Platform," said Dr. Igor Fisch, CEO, Selexis SA. "This agreement represents Selexis' commitment to helping our clients bring biologic therapeutic drugs into the clinic. We look forward to continuing to work with CSL."  

Terms of the agreement were not disclosed.

About Selexis SA

Headquartered in Geneva, Switzerland, Selexis SA is a privately held biotechnology company dedicated to the development of innovative technologies and world-class expert services that significantly reduce the time, effort, and costs associated with developing high-performance mammalian cell lines for therapeutic protein production (i.e. MAbs, growth factors, enzymes). The Company's SURE Cell Line Development™ Technology Platform is based on Selexis Genetic Elements™ -- novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. The technology platform also includes Selexis SUREtech Vectors™, Selexis SUREfection™ Transfection Methods, Selexis SUREvariant Screening™ and the proprietary Selexis SURE CHO-M Cell Line™.

For more information visit www.selexis.com

About CSL Limited

Headquartered in Melbourne, Australia, with major facilities in Germany, Switzerland and the U.S., CSL has more than 10,000 employees working in 27 countries. The CSL Group has a combined heritage of outstanding contribution to medicine and human health with more than 90 years of experience in the development and manufacture of vaccines and plasma protein biotherapies. In fiscal 2010, the company produced revenues of approximately A$4.5 billion.

For more information visit http://www.csl.com.au  

Media Contact: Robert Meister, (602) 953-1716


'/>"/>
SOURCE Selexis SA
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. World TB Day Donation Campaign Increases Access to Improved TB Tests in Resource-Limited Settings
2. Healthzone Limited Engages The Trout Group for Investor Relations Services
3. Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
4. New President and CEO appointed at Ocean Nutrition Canada Limited
5. O2h Continues to Support Senexis to Support Patent Filing Senexis Limited
6. The Independent Committee of the Board of Directors of Tongjitang Appoints Morgan Stanley Asia Limited as Its Financial Advisor
7. Waytronx Announces Agreement for Development and Production of Its GASPT2 Device With UK-Based Ingenion Design Limited
8. DiscoveRx Corp. & Jubilant Biosys Limited Announce Co-Marketing Agreement for Screening Services
9. Bunge Limited to Expand Sugar and Bioenergy Business in Brazil
10. Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced
11. Optimization and Scale-up of a Hydrodynamically Limited Anti-Solvent Crystallization Process: From Lab to Plant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... September 20, 2017 , ... Proscia ... Pathology , a provider of whole slide imaging solutions, are hosting a pre-conference ... workshop, entitled “Successfully Deploying a Best-in-Class Strategy for Digital Pathology,” will feature Proscia ...
(Date:9/20/2017)... ... September 20, 2017 , ... Foresight Institute, a leading ... transformative technologies, announced the winners for the 2017 Foresight Institute Feynman Prizes.These are ... nanotechnology/molecular manufacturing. , Established in 1993 and named in honor of pioneer physicist ...
(Date:9/19/2017)... ... September 19, 2017 , ... Participants of this ... high-performance fume hood. Along with the advantages and disadvantages of ductless, filtered fume ... hoods in the laboratory. , Attendees will learn from an industry expert about ...
(Date:9/19/2017)... ... September 19, 2017 , ... The new and improved Oakton® ... pocket testers even stand upright with a new cap design that is versatile, functional ... the field who need to test water quality. , The Oakton pocket testers have ...
Breaking Biology Technology:
(Date:4/6/2017)... , April 6, 2017 Forecasts ... ANPR, Document Readers, by End-Use (Transportation & Logistics, Government ... Oil, Gas & Fossil Generation Facility, Nuclear Power), Industrial, ... Other) Are you looking for a definitive ... ...
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
(Date:3/28/2017)... March 28, 2017 The report ... (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), ... - Global Forecast to 2022", published by MarketsandMarkets, the ... and is projected to reach USD 75.64 Billion by ... 2022. The base year considered for the study is ...
Breaking Biology News(10 mins):